Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase I Study of FLX925, a Dual FLT3 and CDK4/6 Inhibitor in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Naval Daver, MD, Daniel A. Pollyea, MD, David A. Rizzieri, MD, Jeanne Palmer, MD, Raajit K. Rampal, MD PhD, Shira Dinner, MD, Dale L. Bixby, MD PhD, Mary-Elizabeth M. Percival, MD, Tibor Kovacsovics, Kebede H. Begna, MD, Alexander E. Perl, MD, Marina Konopleva, MD PhD, Lisa Seitz, MS, Jenny McKinnell, Daniel T Johnson, BS, William Ho, MD PhD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1343.

https://doi.org/10.1182/blood.V130.Suppl_1.1343.1343

Published: 2017

Journal Articles

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Dale Bixby, MD PhD, Matthew J. Wieduwilt, MD PhD, Luke Paul Akard, MD, H. Jean Khoury, MD, Pamela S. Becker, MD PhD, Edward H. Van Der Horst, PhD, William Ho, MD PhD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3809.

https://doi.org/10.1182/blood.V126.23.3809.3809

Published: 2015

Journal Articles

Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Herbert Eradat, MD, MS, Sebastian Grosicki, MD, PhD, John Catalono, MD, Walter Cosolo, MD, Irina Dyagil, Thomas J Kipps, MD, PhD, Beiyao Zheng, Sreeni Yalamanchili, Srikumar Sahasranaman, Deborah Hurst, MD, William Ho, MD, PhD, Halyna Pylypenko, MD

Blood (2012) 120 (21): 190.

https://doi.org/10.1182/blood.V120.21.190.190

Published: 2012

Journal Articles

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ranjana Advani, MD, Daniel Lebovic, MD, Mark Brunvand, MD, Andy I. Chen, MD, PhD, Andre Goy, MD, Julie E. Chang, MD, Lauren S Maeda, MD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Bruce D. Cheson, MD

Blood (2012) 120 (21): 59.

https://doi.org/10.1182/blood.V120.21.59.59

Published: 2012

Journal Articles

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, MPH, Manish Patel, MD, Randeep Sangha, MD, Myron S. Czuczman, MD, Gilles Andre Salles, MD, PhD, Franck Morschhauser, MD, Ranjana Advani, MD, Oliver W. Press, MD, PhD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Sarit E. Assouline, MD

Blood (2012) 120 (21): 56.

https://doi.org/10.1182/blood.V120.21.56.56

Published: 2012

Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Suzanne Trudel, MD, P. Leif Bergsagel, MD, Seema Singhal, M.D., Ruben Niesvizky, MD, Raymond L. Comenzo, MD, William I. Bensinger, MD, Daniel Lebovic, MD, YounJeong Choi, Dan Lu, Dorothy French, Elicia Penuel, William Ho, MD, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4029.

https://doi.org/10.1182/blood.V120.21.4029.4029

Published: 2012

Journal Articles

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Jonathan W. Friedberg, MD, Julie M. Vose, M.D., Brad S Kahl, MD, Mark W. Brunvand, MD, Andre Goy, MD, Yvette L. Kasamon, Bart Burington, Ph.D, Jing Li, PhD, William Ho, MD, PhD, Bruce D. Cheson, MD

Blood (2009) 114 (22): 3742.

https://doi.org/10.1182/blood.V114.22.3742.3742

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

A Phase I Study of FLX925, a Dual FLT3 and CDK4/6 Inhibitor in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Email alerts

ASH Publications

American Society of Hematology

Update search

A Phase I Study of FLX925, a Dual FLT3 and CDK4/6 Inhibitor in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only